Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.41 USD | +3.87% | +2.97% | -2.42% |
May. 28 | Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday | MT |
May. 28 | Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical Royalties
100.0
%
| 2,237 | 100.0 % | 2,355 | 100.0 % | +5.24% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2,237 | 100.0 % | 2,355 | 100.0 % | +5.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Arthur McGivern
CIO | Chief Investment Officer | - | 22-10-11 |
Marshall Urist
CTO | Chief Tech/Sci/R&D Officer | 48 | 12-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-20 |
James Reddoch
CTO | Chief Tech/Sci/R&D Officer | 54 | 08-06-30 |
Brienne Kugler
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Sara Klymkowsky
CTO | Chief Tech/Sci/R&D Officer | - | 11-12-31 |
George Lloyd
CIO | Chief Investment Officer | 64 | 10-12-31 |
George Grofik
IRC | Investor Relations Contact | - | 19-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Ted Love
BRD | Director/Board Member | 65 | 20-07-29 |
Henry Fernandez
BRD | Director/Board Member | 65 | 20-07-29 |
Gregory Norden
BRD | Director/Board Member | 66 | 20-02-10 |
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Mario Giuliani
BRD | Director/Board Member | 52 | 20-05-31 |
Bonnie Bassler
BRD | Director/Board Member | 61 | 20-06-15 |
57 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 50,000 | 0 | 0 | 85.52 % |
Stock B | 1 | 146,456,241 | 0 | 0 | |
Stock C | 1 | 450,981,030 | 385,668,432 ( 85.52 %) | 0 |
Company contact information
Royalty Pharma Plc
110 East 59th Street 33rd floor
10022, New York
+212 883 0200
http://www.royaltypharma.comGroup companies
Name | Category and Sector |
---|---|
Royalty Pharma Holdings Ltd.
Royalty Pharma Holdings Ltd. Financial ConglomeratesFinance Royalty Pharma Holdings Ltd. operates as an investment holding company. The company was founded on February 10, 2020 and is headquartered in Bristol, the United Kingdom. |
Financial Conglomerates
|
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.42% | 12.36B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- RPRX Stock
- Company Royalty Pharma plc